OBJECTIVE: To determine the effectiveness of cancer control afforded by radical prostatectomy (RP) in patients with clinical stage T3 prostate cancer. PATIENTS AND METHODS: We retrospectively reviewed data for patients treated by RP for clinical stage T3 prostate cancer between 1995 and 2005. The following case characteristics were analysed: patient age, clinical presentation, preoperative prostate-specific antigen (PSA) level, Gleason score, tumour stage (2002 Tumour-Node-Metastasis), surgical procedure, pathological data, margin and lymph node status, and recurrence. Biochemical recurrence was defined as an increase in PSA level of >0.2 ng/mL after surgery. Kaplan-Meier survival curves were generated, and prognostic factors were evaluated. RESULTS: Overall, 100 patients were included; only 79% of them had pT3 disease based on the pathological specimen. The median follow-up after RP was 69 months. The RP was open in 77 and laparoscopic in 23, with no significant difference between these approaches (P = 0.38). The 5-year PSA-free survival after surgery was 45%, and 5-year cancer-specific survival was 90%. On univariable analysis, Gleason score >7 (P = 0.01), pathological stage (pT2-T3a vs T3b) (P < 0.001), positive lymph node (P < 0.001), and positive margin (P < 0.001) were associated with recurrence. On multivariable analysis, lymph node, margin status and Gleason score were also significant (P < 0.05). CONCLUSIONS: RP can be recommended as an alternative primary treatment that results in acceptable cancer control for clinical stage T3 prostate cancer in selected cases. However, the patient should be warned that surgery alone might not be sufficient to control the cancer, and that adjuvant therapy might be needed during the course of the disease.
OBJECTIVE: To determine the effectiveness of cancer control afforded by radical prostatectomy (RP) in patients with clinical stage T3 prostate cancer. PATIENTS AND METHODS: We retrospectively reviewed data for patients treated by RP for clinical stage T3 prostate cancer between 1995 and 2005. The following case characteristics were analysed: patient age, clinical presentation, preoperative prostate-specific antigen (PSA) level, Gleason score, tumour stage (2002 Tumour-Node-Metastasis), surgical procedure, pathological data, margin and lymph node status, and recurrence. Biochemical recurrence was defined as an increase in PSA level of >0.2 ng/mL after surgery. Kaplan-Meier survival curves were generated, and prognostic factors were evaluated. RESULTS: Overall, 100 patients were included; only 79% of them had pT3 disease based on the pathological specimen. The median follow-up after RP was 69 months. The RP was open in 77 and laparoscopic in 23, with no significant difference between these approaches (P = 0.38). The 5-year PSA-free survival after surgery was 45%, and 5-year cancer-specific survival was 90%. On univariable analysis, Gleason score >7 (P = 0.01), pathological stage (pT2-T3a vs T3b) (P < 0.001), positive lymph node (P < 0.001), and positive margin (P < 0.001) were associated with recurrence. On multivariable analysis, lymph node, margin status and Gleason score were also significant (P < 0.05). CONCLUSIONS: RP can be recommended as an alternative primary treatment that results in acceptable cancer control for clinical stage T3 prostate cancer in selected cases. However, the patient should be warned that surgery alone might not be sufficient to control the cancer, and that adjuvant therapy might be needed during the course of the disease.
Authors: Kien Nguyen; Stephanie Eltz; Sarah J Drouin; Eva Comperat; François Audenet; Raphaele Renard-Penna; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; François Richard; Olivier Cussenot; Morgan Rouprêt Journal: World J Urol Date: 2009-05-23 Impact factor: 4.226
Authors: Marius Kinčius; Aivaras Jonas Matjošaitis; Darius Trumbeckas; Ramūnas Mickevičius; Daimantas Milonas; Mindaugas Jievaltas Journal: Cent European J Urol Date: 2011-03-18
Authors: Anup A Vora; Daniel Marchalik; Keith J Kowalczyk; Hannah Nissim; Gaurav Bandi; Kevin G McGeagh; John H Lynch; S Reza Ghasemian; Mohan Verghese; Krishnan Venkatesan; Phillip Borges; Edward M Uchio; Jonathan J Hwang Journal: Prostate Int Date: 2013-01-21
Authors: Hanna T Sjoberg; Yiannis Philippou; Anette L Magnussen; Iain D C Tullis; Esther Bridges; Andrea Chatrian; Joel Lefebvre; Ka Ho Tam; Emma A Murphy; Jens Rittscher; Dina Preise; Lilach Agemy; Tamar Yechezkel; Sean C Smart; Paul Kinchesh; Stuart Gilchrist; Danny P Allen; David A Scheiblin; Stephen J Lockett; David A Wink; Alastair D Lamb; Ian G Mills; Adrian Harris; Ruth J Muschel; Boris Vojnovic; Avigdor Scherz; Freddie C Hamdy; Richard J Bryant Journal: Br J Cancer Date: 2021-06-21 Impact factor: 7.640